adenosine has been researched along with thiophenes in 264 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.38) | 18.7374 |
| 1990's | 18 (6.82) | 18.2507 |
| 2000's | 33 (12.50) | 29.6817 |
| 2010's | 210 (79.55) | 24.3611 |
| 2020's | 2 (0.76) | 2.80 |
| Authors | Studies |
|---|---|
| Berman, RF; Bruns, RF; Janusz, CA | 1 |
| Rozenberg, MC; Walker, CM | 1 |
| Eglen, RM; Flippin, LA; Kim, EJ; Lazar, DA; Leung, E; Seran, CS; Walsh, LK; Wong, EH | 1 |
| Belardinelli, L; Bruns, RF; Dennis, D; Kollias-Baker, C; Linden, J; Ruble, J | 1 |
| Belardinelli, L; Kollias-Baker, C; Pelleg, A; Xu, J | 1 |
| Amoah-Apraku, B; Belardinelli, L; Bruns, RF; Lu, JY; Pelleg, A; Xu, J | 1 |
| Glofcheski, DJ; Kruuv, J | 1 |
| Berman, RF; Janusz, CA | 1 |
| Bruns, RF; Montamat, SC; Mudumbi, RV; Vestal, RE | 1 |
| Daly, JW; Moni, RW; Romero, FS | 1 |
| Bhattacharya, S; Linden, J | 1 |
| Dayne Mayfield, R; Larson, G; Orona, RA; Zahniser, NR | 1 |
| Belardinelli, L; Dennis, DM; Martens, JR; Raatikainen, MJ | 1 |
| Belardinelli, L; Harrison, JK; Jacobson, M; Kollias-Baker, CA; Ozeck, M; Ruble, J; Shryock, JC | 1 |
| Brandts, B; Bünemann, M; Hluchy, J; Pott, L; Sabin, GV | 1 |
| Gidday, JM; Zhu, Y | 1 |
| Richardt, G; Schreieck, J | 1 |
| IJzerman, AP; Kourounakis, AP; van der Klein, PA | 1 |
| Cox, BF; Gessner, G; Jarvis, MF; Martin, GE; Merkel, L; Myers, M; Shapiro, G | 1 |
| Belardinelli, L; Dennis, DM; Martynyuk, AE; Morey, TE; Seubert, CN; Zima, A | 1 |
| Bantel, C; Childers, SR; Conklin, D; Eisenach, JC; Li, X | 1 |
| de Ligt, RA; IJzerman, AP; Klaasse, E; Leurs, R; Lorenzen, A; Milligan, G; Roerink, SF | 1 |
| de Ligt, RA; IJzerman, AP; Leurs, R; Lorenzen, A; Rivkees, SA | 1 |
| Halenda, SP; Shen, J; Sturek, M; Wilden, PA | 1 |
| Beukers, MW; de Grip, WJ; Ijzerman, AP; Klaasse, EC; Roerink, SF; van den Hout, G | 1 |
| Bhattacharya, S; Ghartey, K; Leonard, M; Linden, J; Tucker, AL; Youkey, RL | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Cattaneo, M | 5 |
| Rich, JD; Wiviott, SD | 1 |
| de Lemos, JA; Wiviott, SD | 1 |
| Alesi, S; Barbarella, G; Brancolini, G; Camaioni, N; Capobianco, ML; Melucci, M; Venturini, A | 1 |
| Angiolillo, DJ | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Capranzano, P | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Biggs, WH; Fabian, MA; Kuriyan, J; Lockhart, DJ; Maly, DJ; Seeliger, MA; Shokat, KM; Statsuk, AV; Zarrinkar, PP | 1 |
| Akram, F; Akram, S; Postuła, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Bishnoi, M; Chopra, K; Kuhad, A | 1 |
| Grove, EL; Kristensen, SD | 2 |
| Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS | 1 |
| Makarov, LM; Serebruany, VL | 1 |
| Aurelio, L; Christopoulos, A; Flynn, BL; Scammells, PJ; Sexton, PM; Valant, C | 1 |
| Kumar, A; Roberts, DH | 1 |
| Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H | 1 |
| Schömig, A | 1 |
| Enkvist, E; Kadak, G; Kriisa, M; Raidaru, G; Roben, M; Uri, A | 1 |
| Collet, JP; Montalescot, G | 1 |
| Franchini, M; Mannucci, PM | 1 |
| Eshaghian, S; Kaul, S; Shah, PK | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| del Río, A; Heras, M | 1 |
| Serebruany, VL | 1 |
| Jilma, B; Krumphuber, J; Siller-Matula, JM | 1 |
| Stone, GW | 1 |
| Cattaneo, M; Podda, GM | 1 |
| Lip, GY; Shantsila, E; Tapp, L | 1 |
| Chen, X; Cong, L; Jin, D; Wang, J; Zhou, W | 1 |
| Brussee, J; Doddareddy, M; Ijzerman, AP; Lane, JR; Lin, J; Narlawar, R | 1 |
| Guo, KW; Tan, JW | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Dixon, SR; Grines, CL; O'Neill, WW | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Gratsianskiĭ, NA | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Abu-Fadel, MS; Dib, C; Hanna, EB | 1 |
| Abbate, A; Agostoni, P; Angiolillo, DJ; Biondi-Zoccai, G; Gaita, F; Lotrionte, M; Romagnoli, E; Sangiorgi, G; Sheiban, I; Testa, L; Valgimigli, M | 1 |
| Tagarakis, GI | 1 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; Nylander, S; van Giezen, H; White, AE | 1 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Samama, M | 1 |
| Hamm, CW; Rassaf, T | 1 |
| Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M | 1 |
| Scharf, RE | 1 |
| Storey, RF | 1 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Easton, JD | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC | 1 |
| Böhm, M; Schirmer, SH | 1 |
| Fadda, V; Maratea, D; Messori, A; Passaro, D | 1 |
| Abbate, A; Agostoni, P; Biondi-Zoccai, G; D'Ascenzo, F; Modena, MG | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G | 1 |
| Chan, MV; Kirkby, NS; Leadbeater, PD; Mitchell, JA; Nylander, S; Warner, TD | 1 |
| D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Alexander, V; Chandra, G; Choi, S; Choi, WJ; Chung, HJ; Gao, ZG; Hou, X; Jacobson, KA; Jeong, LS; Kim, HO; Kim, K; Lee, HW; Lee, JH; Lee, SK; Lee, Y; Majik, MS; Park, SG; Phan, K; Pyee, Y | 1 |
| Collet, JP; De Luca, L; Wouter Jukema, J | 1 |
| Damman, P; de Winter, RJ; James, SK; Kuijt, WJ; Woudstra, P | 1 |
| Braunwald, E | 1 |
| Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL | 1 |
| Janknegt, R; Ruiters, L; Ten Cate, H | 1 |
| Davies, JE; Francis, DP; Nijjer, SS | 1 |
| Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM | 1 |
| Kern, MJ | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA | 1 |
| Grześk, G; Koziński, M; Kubica, J | 1 |
| Grajek, S | 1 |
| James, S; Varenhorst, C | 1 |
| Ferro, A; Floyd, CN; Passacquale, G | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA | 1 |
| Alexopoulos, D; Goudas, P; Kassimis, G; Stavrou, EF; Xanthopoulou, I | 1 |
| Díez, JG; Kuritzky, L | 1 |
| Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T | 1 |
| Hussar, DA | 1 |
| Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Grove, EL; Hvas, AM; Kristensen, SD | 1 |
| Budaj, A; Gurbel, PA; Tantry, US | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Atar, D; Serebruany, VL | 1 |
| Dechant, LM | 1 |
| Huber, K | 1 |
| Harrison, P | 1 |
| Bernlochner, I; Sibbing, D | 1 |
| Kastrati, A | 1 |
| Wenger, NK | 1 |
| Beer, J; Gebhard, C | 1 |
| Bhatt, DL; Croce, KJ; Huang, PH; Resnic, FS | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Kassimis, G; Koutsogiannis, N; Makris, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
| Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Bevilacqua, M; Cirillo, P; D'Anna, C; De Rosa, R; Di Gioia, G; Galasso, G; Niglio, T; Piccolo, R; Piscione, F; Strisciuglio, T | 1 |
| Kiss, RG | 1 |
| Cenci, C; Cioni, G; Gensini, GF; Giusti, B; Lombardi, A; Marcucci, R | 1 |
| Massberg, S; Orban, M; Sibbing, D | 1 |
| Agrawal, K; Bhatt, DL | 1 |
| Hashimoto, M; Jakubowski, J; Ogawa, T; Ohno, K; Sugidachi, A; Tomizawa, A | 1 |
| Clemmensen, P; Dridi, NP; Holmvang, L | 1 |
| Aronow, WS | 1 |
| Barton, C; Dillon, C; Kaye, S; Kjær, S; Knowles, PP; Kostelecky, B; Linch, M; McDonald, NQ; Murray-Rust, J; Parker, PJ; Patel, B; Purkiss, A; Riou, P; Roffey, J; Rosse, C; Soriano, E; Soudy, C | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Alexopoulos, D; Davlouros, P; Siapika, A; Stavrou, K; Theodoropoulos, KC; Tsoni, E; Xanthopoulou, I | 1 |
| Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Santini, A; Valenti, R | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Stiefelhagen, P | 1 |
| Wang, H; Wang, WE; Wang, X; Zeng, C | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Kassimis, G; Koutsogiannis, N; Makris, G; Theodoropoulos, K; Tsigkas, G; Xanthopoulou, I | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| Coleman, CI; Limone, BL | 2 |
| Eikelboom, J; Fitchett, D; Mazer, CD; Verma, S | 1 |
| Oprea, AD; Popescu, WM | 1 |
| Enar, R | 1 |
| Göddertz, R | 1 |
| Augoustides, JG; Lane, B; Patel, PA | 1 |
| Albert, A; Rassaf, T | 1 |
| Alexopoulos, D; Davlouros, P; Hahalis, G; Kakkavas, A; Koutsogiannis, N; Mavronasiou, E; Moulias, A; Xanthopoulou, I | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 1 |
| Huber, K; Lip, GY | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Auffray, JP; Bessereau, J; Bonello, L; Brun, PM; Champenois, A; Fournier, N; Luigi, S; Mazille, A; Meyran, D; Michelet, P; Paganelli, F; Toesca, R; Yvorra, S | 1 |
| Siasos, G; Stefanadis, C; Tousoulis, D | 1 |
| Abbate, R; Antoniucci, D; Parodi, G | 1 |
| Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A | 1 |
| Alves, CM; Caixeta, AM; Carvalho, AC; Carvalho, L; Chan, M; Falcão, FJ | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Moertl, D; Steiner, S | 1 |
| Ha, H; Hwang, I; Jeong, LS; Lee, HW; Lee, J; Lee, JH | 1 |
| Grove, EL; Würtz, M | 1 |
| Chua, D; Nishi, C | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Barnay, P; Berbis, J; Bessereau, J; Bonello, L; Camilleri, E; Dignat-George, F; Frère, C; Helal, O; Laine, M; Michelet, P; Paganelli, F; Pansieri, M; Ronsin, O; Toesca, R | 1 |
| Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Lambert, M; Morange, P; Pankert, M; Quilici, J; Verdier, V | 2 |
| Casassus, F; Fiore, M; Horovitz, A; Leroux, L; Pons, AC | 1 |
| Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE | 1 |
| Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I | 1 |
| Angiolillo, DJ; Curzen, N; Effron, MB; Gurbel, P; Jakubowski, JA; Li, W; Lipkin, F; Trenk, D; Vaitkus, P; Zettler, M | 1 |
| Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
| Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Hirschl, MM | 1 |
| Jover, E; Tello-Montoliu, A; Valdés, M | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Colombo, P; Klugmann, S; Mafrici, A; Morici, N; Oreglia, JA; Savonitto, S | 1 |
| Bonhomme, F; Fontana, P; Reny, JL | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C | 1 |
| Aronson, D | 1 |
| Aurelio, L; Baltos, JA; Christopoulos, A; Chuo, CH; May, LT; Scammells, PJ; Sexton, PM; Valant, C; White, PJ | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Caldeira, D; Ferreira, JJ; Pinto, FJ | 1 |
| Bouatou, Y; Gabrielli, A; Saudan, P | 1 |
| Balsarotti, J; Briley, A; Dufner-Beattie, J; Noueiry, A; O'Guin, A; O'Guin, S; Olivo, PD; Rice, CM; Roth, R; Slomczynska, U; Starkey, G; Wang, B | 1 |
| Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU | 1 |
| Taylor, J | 1 |
| Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D | 1 |
| Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL | 1 |
| Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P | 1 |
| Elosua, R; Marrugat, J; Vila, J | 2 |
| Catalá-López, F | 1 |
| Fortmann, SD; Serebruany, VL | 1 |
| Massberg, S; Sibbing, D | 1 |
| Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S | 1 |
| Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI | 1 |
| Alexopoulos, D; Bampouri, T; Gkizas, V; Koniari, I; Kontoprias, K; Perperis, A; Stavrou, K; Vogiatzi, C; Xanthopoulou, I | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo Silberman, S; Sideris, G; Voicu, S | 1 |
| Kornowski, R; Lerman-Shivek, H; Lev, EI; Orvin, K; Perl, L; Rechavia, E; Vaduganathan, M; Weissler-Snir, A; Zemer-Wassercug, N | 1 |
| Antoniucci, D; Bellandi, B; Parodi, G | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Morange, P; Pankert, M; Quilici, J | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Vengoechea, F | 1 |
| Bhatiya, A; Eguale, T; Gunn, JS; Koopman, JA; Kwiek, JJ; Marshall, JM | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG | 1 |
| Alexopoulos, D; Antoniucci, D; Bellandi, B; Capodanno, D; Capranzano, P; Migliorini, A; Parodi, G; Stavrou, K; Tamburino, C; Valenti, R; Xanthopoulou, I | 1 |
| Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K | 1 |
| Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L | 1 |
| Jiang, M; You, JH | 1 |
| Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Keaney, JF | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Bonello, L; Cluzel, M; Dignat-George, F; Frere, C; Gaubert, M; Guieu, R; Hasan, A; Kerbaul, F; Laine, M; Mancini, J; Michelet, P; Paganelli, F; Thuny, F | 1 |
| Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW | 1 |
| Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S | 1 |
| Christopoulos, A; Chuo, CH; Devine, SM; Krum, H; May, LT; Scammells, PJ; Wang, BH; White, PJ | 1 |
| Baltos, JA; Christopoulos, A; Chuo, CH; Ford, L; May, LT; Scammells, PJ; Vecchio, EA; Wang, BH; White, PJ | 1 |
| Parker, WA; Storey, RF | 1 |
| Aurelio, L; Baltos, JA; Christopoulos, A; Devine, SM; Ford, L; Jörg, M; May, LT; Nguyen, ATN; Scammells, PJ; Valant, C; White, PJ | 1 |
| Cooper, SL; Hill, SJ; Jörg, M; March, J; Sabbatini, AR; Scammells, PJ; Woolard, J | 1 |
| Garrett, TJ; Giancotti, LA; Harada, CM; Harmon, TA; Kolar, G; Lauro, F; Salvemini, D | 1 |
127 review(s) available for adenosine and thiophenes
| Article | Year |
|---|---|
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
New antiplatelet therapies for acute coronary syndromes.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Pharmacology of emerging novel platelet inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Advances in antiplatelet therapy: agents in clinical development.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on oral antiplatelet therapy: principles, problems and promises.
Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Tetrazoles; Thiophenes; Thromboxane A2; Ticagrelor | 2009 |
Emerging P2Y12 receptor antagonists: role in coronary artery disease.
Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2010 |
New P2Y12 blockers.
Topics: Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
New antiplatelet agents: why they are needed.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor | 2009 |
Advances in antiplatelet treatment for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor | 2010 |
State of the art of new P2Y12 antagonists.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
A new era for antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome | 2010 |
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome | 2011 |
Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents.
Topics: Adenosine; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor | 2010 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Current options to manage clopidogrel poor responsiveness].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Update on anti-platelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor | 2011 |
Ticagrelor for acute coronary syndrome?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
P2Y12 platelet inhibition in clinical practice.
Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
InforMatrix: ADP antagonists in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor | 2012 |
Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
Topics: Acute Coronary Syndrome; Adenosine; Hemorrhage; Humans; Myocardial Ischemia; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Meeting new challenges with antiplatelet therapy in primary care.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Health Care; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
New drugs 2012, part 2.
Topics: Abatacept; Adenosine; Aminoglycosides; Bradykinin; Deferiprone; Drug Approval; Fidaxomicin; Growth Hormone-Releasing Hormone; Humans; Immunoconjugates; Morpholines; Nitriles; Pyridones; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rilpivirine; Rivaroxaban; Thiophenes; Ticagrelor | 2012 |
[Platelet function: new drugs, new assays : possible impacts on operative medicine?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Antiplatelet therapy beyond 2012: role of personalized medicine.
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
UA/NSTEMI: Are you following the latest guidelines?
Topics: Adenosine; Angina, Unstable; Anticoagulants; Blood Glucose; Guideline Adherence; Humans; Kidney Failure, Chronic; Myocardial Infarction; Patient Education as Topic; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Advances in the monitoring of anti-P2Y12 therapy.
Topics: Adenosine; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Thienopyridines and other ADP-receptor antagonists.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
New anti-platelet agents: the end of resistance?
Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice guide
Topics: Adenosine; Administration, Oral; Angina, Unstable; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Treatment Outcome; Warfarin | 2012 |
[Platelet inhibitors in clinical practice].
Topics: Acute Coronary Syndrome; Adenosine; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Interactions; Drug Resistance; Drugs, Investigational; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor | 2012 |
Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation.
Topics: Adenosine; Administration, Oral; Algorithms; Coronary Disease; Elective Surgical Procedures; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticagrelor | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticagrelor | 2014 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
Antiplatelets in acute coronary syndrome: personal perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidol; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2012 |
Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor | 2013 |
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Progress in platelet blockers: the target is the P2Y12 receptor.
Topics: Adenosine; Adenosine Monophosphate; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents for cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[New antiplatelet drugs in coronary artery disease].
Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Prasugrel and ticagrelor: is there a winner?
Topics: Adenosine; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
How to manage prasugrel and ticagrelor in daily practice.
Topics: Adenosine; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Israel; Piperazines; Platelet Aggregation Inhibitors; Population Groups; Prasugrel Hydrochloride; Reproducibility of Results; Thiophenes; Ticagrelor | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor | 2014 |
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
19 trial(s) available for adenosine and thiophenes
| Article | Year |
|---|---|
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Topics: Adenosine; Aged; Blood Platelets; Drug Administration Schedule; Female; Greece; Humans; Least-Squares Analysis; Linear Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Single-Blind Method; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2012 |
Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2013 |
Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients.
Topics: Adenosine; Blood Platelets; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Topics: Adenosine; Aged; Aged, 80 and over; Comparative Effectiveness Research; Drug Monitoring; Electrocardiography; Female; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2013 |
Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Intravenous; Aged; Area Under Curve; Blood Flow Velocity; Coronary Circulation; Cross-Over Studies; Echocardiography, Doppler; Female; Greece; Humans; Least-Squares Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Single-Blind Method; Thiophenes; Ticagrelor; Treatment Outcome; Vasodilator Agents | 2013 |
Ticagrelor or prasugrel for pre-hospital protocols in STEMI?
Topics: Adenosine; Aged; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Diabetes Mellitus; Female; France; Humans; Hypoglycemic Agents; Insulin; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Pilot Projects; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome | 2013 |
Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
Topics: Adenosine; Adolescent; Adult; Aged; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome; Young Adult | 2014 |
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome | 2014 |
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome; Young Adult | 2015 |
118 other study(ies) available for adenosine and thiophenes
| Article | Year |
|---|---|
Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice.
Topics: Adenosine; Animals; Evoked Potentials; Hippocampus; In Vitro Techniques; Male; Neural Pathways; Neurons; Pyramidal Tracts; Rats; Receptors, Purinergic; Thiophenes | 1991 |
The effect of pyrimidine compounds on the potentiation of adenosine inhibition of aggregation, on adenosine phosphorylation and phosphodiesterase activity of blood platelets.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Carbon Isotopes; Cyclic AMP; Dipyridamole; Ethanolamines; Ethylamines; Humans; In Vitro Techniques; Morpholines; Phosphoric Diester Hydrolases; Piperidines; Platelet Adhesiveness; Pyrimidines; Thiophenes | 1973 |
Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro.
Topics: Adenosine; Adenosine Deaminase Inhibitors; Aminoimidazole Carboxamide; Animals; Electric Stimulation; Guinea Pigs; Heart Atria; Ileum; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Male; Muscle Contraction; Myocardial Contraction; Peptides; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyridines; Receptors, Purinergic P1; Ribonucleosides; Thienopyridines; Thiophenes; Wasp Venoms | 1995 |
Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine.
Topics: Adenosine; Allosteric Regulation; Animals; Binding Sites; Brain; Bundle of His; Drug Synergism; Female; Guinea Pigs; Heart; Humans; In Vitro Techniques; Male; Membranes; Myocardium; Piperazines; Radioligand Assay; Receptors, Purinergic P1; Thiophenes | 1994 |
Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine.
Topics: Adenosine; Animals; Atrioventricular Node; Bundle of His; Coronary Vessels; Female; Guinea Pigs; Hypoxia; In Vitro Techniques; Male; Piperazines; Receptors, Purinergic P1; Thiophenes; Tubercidin; Vasodilation | 1994 |
Selective potentiation by an A1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart.
Topics: Adenosine; Animals; Depression, Chemical; Dose-Response Relationship, Drug; Drug Synergism; Female; Guinea Pigs; Heart Conduction System; In Vitro Techniques; Male; Receptors, Purinergic; Thiophenes | 1993 |
Further evidence for two modes of hypothermia damage.
Topics: Adenosine; Animals; Cell Death; Cell Division; Cell Line; Cell Survival; Cold Temperature; Cricetinae; Cricetulus; Cryopreservation; Cryoprotective Agents; Glycine; Thermodynamics; Thiophenes; Thiourea; Time Factors | 1993 |
The adenosine binding enhancer, PD 81,723, inhibits epileptiform bursting in the hippocampal brain slice.
Topics: Adenosine; Animals; Axons; Electric Stimulation; Epilepsy; Hippocampus; In Vitro Techniques; Magnesium; Male; Neurons; Pyramidal Tracts; Rats; Thiophenes | 1993 |
Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor.
Topics: Adenosine; Allosteric Regulation; Animals; Atrial Function; Depression, Chemical; Drug Synergism; Heart; Heart Atria; Heart Rate; Male; Myocardial Contraction; Rats; Rats, Sprague-Dawley; Receptors, Purinergic; Theophylline; Thiophenes; Xanthines | 1993 |
The amphiphilic peptide adenoregulin enhances agonist binding to A1-adenosine receptors and [35S]GTP gamma S to brain membranes.
Topics: Adenosine; Adrenergic alpha-Agonists; Amphibian Proteins; Animals; Antimicrobial Cationic Peptides; Brain; Cell Line; Cell Membrane; Cyclic AMP; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Kinetics; Magnesium Chloride; Peptides; Purinergic P1 Receptor Agonists; Ranidae; Rats; Receptors, Purinergic P1; Sodium Chloride; Sulfur Radioisotopes; Thiophenes; Tritium; Xanthines | 1995 |
Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors.
Topics: Adenosine; Allosteric Regulation; Animals; CHO Cells; Cricetinae; Cyclic AMP; Down-Regulation; Humans; Kinetics; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptors, Purinergic P1; Recombinant Proteins; Thiophenes; Transfection | 1996 |
Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.
Topics: Adenosine; Animals; Antihypertensive Agents; Basal Ganglia; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Male; Phenethylamines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Purinergic P1; Tetrahydronaphthalenes; Thiophenes | 1996 |
Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart.
Topics: Adenosine; Allosteric Regulation; Animals; Atrioventricular Node; Biological Transport; Body Fluids; Enzyme Inhibitors; Guinea Pigs; Heart; Heart Conduction System; In Vitro Techniques; Myocardium; Nucleosides; Pericardium; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Tubercidin | 1996 |
Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor.
Topics: Adenosine; Adenosine Deaminase; Allosteric Regulation; Animals; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Recombinant Proteins; Thiophenes; Xanthines | 1997 |
Inhibition of muscarinic K+ current in guinea-pig atrial myocytes by PD 81,723, an allosteric enhancer of adenosine binding to A1 receptors.
Topics: Adenosine; Allosteric Regulation; Animals; Cells, Cultured; Female; Guinea Pigs; Heart Atria; Male; Potassium Channel Blockers; Receptors, Muscarinic; Receptors, Purinergic P1; Thiophenes | 1997 |
Endothelium-dependent changes in retinal blood flow following ischemia.
Topics: Acetylcholine; Adenosine; Animals; Animals, Newborn; Blood Flow Velocity; Endothelin Receptor Antagonists; Endothelium, Vascular; Enzyme Inhibitors; Fluorescein Angiography; Hyperoxia; Hypoxia; Ischemia; Isoxazoles; Nitric Oxide Synthase; omega-N-Methylarginine; Reperfusion; Retinal Vessels; Swine; Thioinosine; Thiophenes | 1998 |
Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart.
Topics: Adenine; Adenosine; Aminoimidazole Carboxamide; Animals; Caffeine; Creatine Kinase; Electrocardiography; Enzyme Inhibitors; Hypoxanthine; Inosine; Male; Myocardial Ischemia; Myocardium; Perfusion; Rats; Rats, Wistar; Reperfusion Injury; Ribonucleosides; Theophylline; Thioinosine; Thiophenes; Time Factors; Ventricular Fibrillation; Xanthines | 1999 |
Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding.
Topics: Adenosine; Allosteric Regulation; Animals; Binding, Competitive; Brain; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Thiophenes; Xanthines | 1999 |
Differential effects of the adenosine A(1) receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes.
Topics: Adenosine; Adipocytes; Allosteric Regulation; Animals; Brain; Dogs; Guinea Pigs; Kinetics; Male; Membranes; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Thiophenes | 1999 |
Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: possible ionic mechanism.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenosine; Animals; Atrioventricular Node; Drug Synergism; Electric Stimulation; Guinea Pigs; Heart Rate; Membrane Potentials; Myocytes, Cardiac; Potassium; Potassium Channels; Thiophenes | 2002 |
Repeated dosing with oral allosteric modulator of adenosine A1 receptor produces tolerance in rats with neuropathic pain.
Topics: Adenosine; Administration, Oral; Allosteric Regulation; Animals; Drug Tolerance; Male; Pain; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Spinal Nerves; Thiophenes; Xanthines | 2004 |
Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi alpha-subunits.
Topics: Adenosine; Allosteric Site; Animals; Binding, Competitive; Cell Membrane; COS Cells; Cysteine; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits, Gi-Go; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Mutation; Radioligand Assay; Receptor, Adenosine A1; Recombinant Fusion Proteins; Sodium Chloride; Sulfur Radioisotopes; Thiophenes; Transfection; Tritium; Xanthines | 2004 |
A "locked-on," constitutively active mutant of the adenosine A1 receptor.
Topics: Adenosine; Animals; Binding, Competitive; Cell Line; Cell Membrane; Chlorocebus aethiops; Colforsin; COS Cells; Cyclic AMP; Guanosine 5'-O-(3-Thiotriphosphate); Guanosine Triphosphate; Humans; Kinetics; Mutation; Plasmids; Radioligand Assay; Receptor, Adenosine A1; Sodium; Sulfur Radioisotopes; Theophylline; Thiophenes; Transfection; Tritium; Xanthines | 2005 |
Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: role for the A1 adenosine receptor.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Amino Acid Sequence; Animals; Cell Proliferation; Cells, Cultured; Cloning, Molecular; Coronary Vessels; DNA; Mitogens; Molecular Sequence Data; Muscle, Smooth, Vascular; Oligonucleotides, Antisense; Organ Culture Techniques; Pertussis Toxin; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptors, Purinergic P1; RNA, Messenger; Sus scrofa; Thiophenes | 2005 |
Allosteric modulators affect the internalization of human adenosine A1 receptors.
Topics: Adenosine; Allosteric Regulation; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Endocytosis; Humans; Luminescent Proteins; Microscopy, Confocal; Radioligand Assay; Receptor, Adenosine A1; Recombinant Fusion Proteins; Thiadiazoles; Thiazoles; Thiophenes; Transfection; Tritium; Xanthines | 2005 |
The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.
Topics: Adenosine; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Allosteric Regulation; Animals; Cell Line; Cyclic AMP; Dogs; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gs; Humans; Iodobenzenes; Kidney; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Radioligand Assay; Receptor, Adenosine A1; Receptor, Adenosine A2A; Recombinant Fusion Proteins; Thiophenes; Transfection; Xanthines | 2006 |
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Water-soluble, electroactive, and photoluminescent quaterthiophene-dinucleotide conjugates.
Topics: Adenosine; Electrochemistry; Hydrogen Bonding; Luminescence; Luminescent Measurements; Models, Molecular; Molecular Structure; Nucleotides; Photochemistry; Solubility; Spectrophotometry, Ultraviolet; Stereoisomerism; Thiophenes; Thymidine; Water | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Tuning a three-component reaction for trapping kinase substrate complexes.
Topics: Adenosine; Cross-Linking Reagents; Cysteine; Fluorescent Dyes; HeLa Cells; Humans; Lysine; Models, Chemical; Molecular Conformation; Peptides; Phosphorylation; Phosphotransferases; Protein Structure, Tertiary; Proteins; Thiophenes | 2008 |
Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain.
Topics: Adenosine; Animals; Cerebral Cortex; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Hot Temperature; Hyperalgesia; Male; Mice; Mice, Inbred Strains; Pain Measurement; Pain Threshold; Selective Serotonin Reuptake Inhibitors; Streptozocin; Thiophenes; Touch | 2009 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Allosteric Regulation; Animals; CHO Cells; Cricetinae; Cricetulus; Extracellular Signal-Regulated MAP Kinases; Humans; Phosphorylation; Thiophenes | 2009 |
Test before you stop.
Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection | 2009 |
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases.
Topics: Adenosine; Arginine; Binding Sites; Cyclic AMP-Dependent Protein Kinases; Peptides; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; rho-Associated Kinases; Thiophenes | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor in ACS: redefining a new standard of care?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Synthesis and antitumor activity of 5'-deoxy-4'-thio-L-nucleosides.
Topics: Adenosine; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship; Thionucleosides; Thiophenes | 2010 |
Hybrid ortho/allosteric ligands for the adenosine A(1) receptor.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Allosteric Site; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Humans; Ligands; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Molecular; Phosphorylation; Radioligand Assay; Receptor, Adenosine A1; Structure-Activity Relationship; Thiophenes | 2010 |
Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, G-Protein-Coupled; Thiophenes; Ticagrelor | 2011 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor | 2011 |
Resistance to anti-platelet agents.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
New antiplatelet agents.
Topics: Adenosine; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2010 |
[Do genetic factors reduce the effects of clopidogrel?].
Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor | 2011 |
Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor (Reply to Passaro et al. - Int J Cardiol 2011).
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Randomized Controlled Trials as Topic; Thiophenes | 2011 |
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Topics: Adenosine; Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2011 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States | 2011 |
Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; HEK293 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Male; Models, Molecular; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A3; Receptors, Adenosine A2; Stereoisomerism; Structure-Activity Relationship; Thiophenes | 2012 |
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report.
Topics: Adenosine; Adult; Drug Resistance; Female; Humans; Kidney Failure, Chronic; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Renal Dialysis; Thiophenes; Ticagrelor | 2013 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?
Topics: Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticagrelor; Treatment Outcome | 2013 |
A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
Topics: Adenosine; Animals; Blood Coagulation Tests; Dose-Response Relationship, Drug; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Risk; Thiophenes; Thrombosis; Ticagrelor | 2013 |
Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes.
Topics: Adenosine; Adenosine Triphosphate; Amino Acid Sequence; Animals; Binding Sites; Cell Line; Cell Movement; Cell Survival; Crystallography, X-Ray; Cytoskeletal Proteins; Dogs; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Isoenzymes; Molecular Mimicry; Molecular Sequence Data; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Thiophenes | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
Topics: Adenosine; Blood Platelets; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
Topics: Adenosine; Blood Platelets; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Coronary heart disease: news about stents and bypasses].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Coronary Disease; Follow-Up Studies; Humans; Myocardial Revascularization; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retreatment; Risk Factors; Stents; Survival Rate; Thiophenes; Ticagrelor | 2013 |
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Mechanisms affecting platelet response to antiplatelet therapy in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Female; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Preoperative Care; Thiophenes | 2013 |
Reply: Mechanisms affecting platelet response to antiplatelet therapy in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine; Female; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Preoperative Care; Thiophenes | 2013 |
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
Topics: Adenosine; Adenosine Diphosphate; Administration, Oral; Adult; Animals; Cell Adhesion Molecules; Clinical Protocols; Enzyme-Linked Immunosorbent Assay; Humans; Macaca fascicularis; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Young Adult | 2013 |
P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Topics: Adenosine; Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Thiophenes; Ticagrelor | 2013 |
The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis.
Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Collagen Type I; Epithelial-Mesenchymal Transition; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Fibronectins; Fibrosis; Gene Expression Regulation; JNK Mitogen-Activated Protein Kinases; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Protein-Lysine 6-Oxidase; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A3; RNA, Messenger; Signal Transduction; Smad Proteins; Thiophenes; Transforming Growth Factor beta1; Ureteral Obstruction | 2013 |
Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Coagulation Tests; Blood Platelets; Cost-Benefit Analysis; Decision Trees; Europe; Humans; Incidence; Markov Chains; Medication Adherence; Monte Carlo Method; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2014 |
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor.
Topics: Adenosine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticagrelor | 2014 |
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine | 2014 |
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.
Topics: Adenosine; Allosteric Site; Animals; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Drug Design; Ligands; Purinergic P1 Receptor Agonists; Rats; Thiophenes | 2014 |
Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
Topics: Adenosine; Antiviral Agents; Biological Assay; Cell Culture Techniques; Cell Line; Cell Survival; Cyclosporine; Furans; Genotype; Hepacivirus; Hepatitis C; High-Throughput Screening Assays; Humans; Luciferases, Renilla; Mutagenesis, Site-Directed; Oligopeptides; Pyridines; Replicon; Thiophenes; Viral Nonstructural Proteins; Virus Replication | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Controversies in acute cardiovascular care.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Is it appropriate to compare the results from two clinical trials with one drug in common?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Evaluation of comparative treatment effects using indirect comparisons.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2013 |
Evaluation of comparative treatment effects using indirect comparisons. Response.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2013 |
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction.
Topics: Adenosine; Adolescent; Adult; Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors | 2015 |
Switching from ticagrelor to prasugrel: a warning.
Topics: Adenosine; Aged; Drug Substitution; Fatal Outcome; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2014 |
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Postoperative Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retrospective Studies; Thiophenes; Thrombosis; Ticagrelor | 2014 |
Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Body Mass Index; Female; Humans; Male; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2014 |
Inhibition of Salmonella enterica biofilm formation using small-molecule adenosine mimetics.
Topics: Acinetobacter baumannii; Adenosine; Adenosine Triphosphate; Anti-Bacterial Agents; Biofilms; Cell Line, Tumor; Chaperonin 60; Hep G2 Cells; Humans; Protein Binding; Pyrimidinones; Salmonella typhi; Salmonella typhimurium; Thiophenes | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Acute Disease; Adenosine; Age Factors; Aged; Analgesics, Opioid; Drug Interactions; Electrocardiography; Female; Humans; Male; Middle Aged; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2015 |
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization | 2014 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Animals; Animals, Newborn; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Thiophenes | 2016 |
The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Allosteric Regulation; Animals; Animals, Newborn; Binding, Competitive; Cell Line; Cells, Cultured; CHO Cells; Collagen; Cricetulus; Fibrosis; Humans; Ligands; Mesangial Cells; Myoblasts, Cardiac; Protective Agents; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2B; Recombinant Proteins; Signal Transduction; Thiophenes | 2016 |
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2016 |
A Structure-Activity Relationship Study of Bitopic N
Topics: Adenosine; Adenosine A1 Receptor Agonists; Allosteric Regulation; Animals; Cricetinae; Humans; Ligands; Phenols; Structure-Activity Relationship; Thiophenes | 2018 |
The effect of two selective A
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Aminopyridines; Animals; Cardiovascular System; Consciousness; Drug Partial Agonism; Heart Rate; Hemodynamics; Ligands; Male; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Regional Blood Flow; Thiazoles; Thiophenes | 2020 |
Role of Adenosine Kinase in Sphingosine-1-Phosphate Receptor 1-Induced Mechano-Hypersensitivities.
Topics: Adenosine; Adenosine Kinase; Animals; Hyperalgesia; Inflammasomes; Interleukin-1beta; NLR Proteins; Oxadiazoles; Rats; Rats, Sprague-Dawley; Sphingosine-1-Phosphate Receptors; Spinal Cord Dorsal Horn; Thiophenes | 2022 |